Last updated on April 25, 2014 at 5:25 EDT

Latest Matthew During Stories

2011-03-17 12:32:49

Results from the first successful phase 2 clinical trial of gene therapy for Parkinson's or any neurologic disorder A gene therapy called NLX-P101 dramatically reduces movement impairment in Parkinson's patients, according to results of a Phase 2 study published today in the journal Lancet Neurology. The approach introduces a gene into the brain to normalize chemical signaling. The study is the first successful randomized, double-blind clinical trial of a gene therapy for Parkinson's or any...